Clinical Trial: Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Condition:
Advanced Lymphoma
Advanced Malignant Solid Neoplasm
Hematopoietic and Lymphoid System Neop
Study Type: Interventional
Official Title: Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations (PTEN Loss Allowed)
Brief Summary:
This phase II MATCH treatment trial identifies the effects of copanlisib hydrochloride (copanlisib) in patients whose cancer has a genetic change called PIK3CA mutation. Copanlisib may stop the growth of cancer cells by blocking PIK3, a protein needed for cell growth. Researchers hope to learn if copanlisib will shrink this type of cancer or stop its growth.
Read more